Cargando…
Controlled release of Clenbuterol from a hydroxyapatite carrier for the treatment of Alzheimer’s Disease
BACKGROUND: Alzheimer’s disease is a neurodegenerative disorder, and Aβ aggregation is considered to be the central process implicated in its pathogenesis. Current treatments are faced by challenges such as serious side effects and reduced drug bioavailability. In this study, we developed a drug del...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557233/ https://www.ncbi.nlm.nih.gov/pubmed/37798744 http://dx.doi.org/10.1186/s40824-023-00432-4 |